Research Analysts Set Expectations for ORMP Q1 Earnings

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) – Stock analysts at Zacks Small Cap issued their Q1 2025 earnings estimates for shares of Oramed Pharmaceuticals in a note issued to investors on Thursday, April 3rd. Zacks Small Cap analyst M. Marin anticipates that the biotechnology company will post earnings per share of ($0.01) for the quarter. The consensus estimate for Oramed Pharmaceuticals’ current full-year earnings is ($0.03) per share. Zacks Small Cap also issued estimates for Oramed Pharmaceuticals’ Q2 2025 earnings at ($0.01) EPS, Q3 2025 earnings at ($0.01) EPS, Q4 2025 earnings at ($0.03) EPS and FY2025 earnings at ($0.07) EPS.

Oramed Pharmaceuticals (NASDAQ:ORMP) last posted its earnings results on Thursday, March 27th. The biotechnology company reported $0.01 EPS for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.04.

Separately, StockNews.com lowered shares of Oramed Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, February 19th.

Oramed Pharmaceuticals Price Performance

NASDAQ:ORMP opened at $2.10 on Monday. Oramed Pharmaceuticals has a 52-week low of $1.96 and a 52-week high of $3.09. The stock’s 50 day moving average price is $2.28 and its 200 day moving average price is $2.34. The company has a market capitalization of $85.79 million, a PE ratio of 19.09 and a beta of 1.50.

Institutional Investors Weigh In On Oramed Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the business. BML Capital Management LLC increased its position in Oramed Pharmaceuticals by 20.9% in the 4th quarter. BML Capital Management LLC now owns 2,643,907 shares of the biotechnology company’s stock valued at $6,398,000 after acquiring an additional 457,716 shares during the period. Boothbay Fund Management LLC grew its stake in shares of Oramed Pharmaceuticals by 2.0% in the 4th quarter. Boothbay Fund Management LLC now owns 845,188 shares of the biotechnology company’s stock valued at $2,045,000 after purchasing an additional 16,857 shares during the last quarter. Peapod Lane Capital LLC acquired a new position in shares of Oramed Pharmaceuticals in the fourth quarter valued at approximately $550,000. Dimensional Fund Advisors LP raised its stake in shares of Oramed Pharmaceuticals by 143.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 118,995 shares of the biotechnology company’s stock worth $288,000 after purchasing an additional 70,190 shares during the last quarter. Finally, Marquette Asset Management LLC acquired a new stake in shares of Oramed Pharmaceuticals during the fourth quarter worth $81,000. 12.73% of the stock is owned by hedge funds and other institutional investors.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.